Acura Pharmaceuticals's quarterly market cap
declined
from Jun. 2021 (€26.17 Mil) to Sep. 2021 (€23.56 Mil) and
declined
from Sep. 2021 (€23.56 Mil) to Dec. 2021 (€23.43 Mil).
Acura Pharmaceuticals's annual market cap
declined
from Dec. 2019 (€3.41 Mil) to Dec. 2020 (€2.86 Mil) but then
increased
from Dec. 2020 (€2.86 Mil) to Dec. 2021 (€23.43 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Acura Pharmaceuticals's Enterprise Value for Today is €1.27 Mil.
Acura Pharmaceuticals (STU:HD4B) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:HD4B vs VFRM, THCT, CBGL: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Acura Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acura Pharmaceuticals Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Acura Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Acura Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Acura Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acura Pharmaceuticals (STU:HD4B) has a Market Cap of €1.15 Mil as of Jul. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Acura Pharmaceuticals and its competitors.
Is Acura Pharmaceuticals' Market Cap too high?
Acura Pharmaceuticals' current Market Cap is €1.15 Mil. Overall, Acura Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Acura Pharmaceuticals' Market Cap compare to VFRM and THCT?
Acura Pharmaceuticals' Market Cap of €1.15 Mil can be compared against companies in the Drug Manufacturers industry. The industry median Market Cap is 212.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 212.74, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Acura Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Market Cap is 212.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acura Pharmaceuticals's current Market Cap is €1.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acura Pharmaceuticals stock overvalued right now?
Acura Pharmaceuticals (STU:HD4B) has a current Market Cap of €1.15 Mil. The current Market Cap is €1.15 Mil. Acura Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Acura Pharmaceuticals (STU:HD4B), the current Market Cap is €1.15 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acura Pharmaceuticals Inc is a drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. It has discovered and developed three proprietary platform technologies which can be used to develop multiple products. Its Limitx Technology is being developed to minimize the risk of overdose, its Aversion Technology is intended to address methods of abuse associated with opioid analgesics while its Impede Technology is directed at minimizing the extraction and conversion of pseudoephedrine, or PSE, into methamphetamine. It operates in single segment being the research, development and commercialization of technologies and products intended to address safe use of medications.
16GF Score
Get the complete analysis for STU:HD4B
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:HD4B has been successfully added to your 
